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Smoking, Lung Function and the Prognosis of Abdominal Aortic
Aneurysm
The UK Small Aneurysm Trial Participants∗†
Background: the UK Small Aneurysm Trial was established to test the benefit of prophylactic elective surgery for small
abdominal aortic aneurysms (4.0–5.5 cm in diameter) and identify prognostic risk factors, including smoking.
Patients, methods and outcomes: one thousand and ninety patients (902 men and 188 women, mean age 69.3 years)
were randomised to either early elective surgery or ultrasonography surveillance until the aneurysm diameter exceeded
5.5 cm, mean follow-up was 4.6 years. Baseline assessments included lung function tests and cotinine (a smoking marker).
The principal outcome measures were all-cause mortality and aneurysm rupture.
Results: during the course of the trial, aneurysm rupture was diagnosed in 25 patients and 309 patients died. Whereas
self-reported smoking status was not significantly associated with survival, patients without any trace of plasma cotinine
had a significantly improved long-term (6-year) survival, p=0.02. Current smokers had a lower FEV1 than past- and
never-smokers. FEV1 was the most powerful predictor of long-term (6-year) survival, the crude death rates per 100
person-years were 9.1, 6.9 and 4.6 for those with FEV1 <1.9 l, 1.9–2.5 l and >2.5 l respectively, p=0.001. Moreover, the
rupture rate was 1.9% per year for patients positive for plasma cotinine compared with 0.5% in those without trace of
plasma cotinine, p=0.004.
Conclusions: self-reported smoking status underestimates the effect of continued smoking on the prognosis of patients
with small abdominal aortic aneurysm. Patients with high plasma cotinine concentrations (smokers) have an increased
risk of aneurysm rupture and poorer long-term survival.
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Introduction surgery was not associated with an improved long-
term survival.4 After 6 years of follow-up the survival
in the early elective surgery arm (563 patients) andAbdominal aortic aneurysm (AAA) is a common con-
the surveillance arm (527 patients) was 64%.4 The costsdition, most often found in older men with a significant
and quality of life in the two treatment arms of thehistory of smoking. There has been considerable debate
UK Small Aneurysm Trial have also been compared.5as to whether patients with small AAAs benefit from
The American trial has not yet reported.prophylactic elective surgical repair, since this pro-
With the principal results of the UK Small Aneurysmcedure carries a significant mortality risk and the risk
Trial having been reported, we now focus attentionof rupture of small aneurysms is thought to be small.1
on other matters important to vascular surgeons. WhatTwo randomized trials were established, one in the
are the important prognostic factors for survival in aU.K. and one in the U.S.A.2,3 Both these trials in-
patient with a small AAA? Which baseline factorsvestigated whether a policy of early elective surgery
indicate an increased risk of aneurysm rupture?provides a better management of small aneurysms
Smoking is the strongest and most consistent risk(4.0–5.5 cm in diameter) than a policy of ul-
factor for the development of abdominal aortic an-trasonographic surveillance, which carries an in-
eurysm.6–9 Smoking has also been indicated as a riskcreased risk of death from aneurysm. The U.K. trial,
factor for aneurysm expansion10 and is associated withwith 1090 patients, reported in 1998. This trial showed
pulmonary dysfunction and disease. Lung functionthat ultrasonographic surveillance was safe, the annual
declines with age. In non-smokers the mean loss ofrupture rate being only 1% and that early elective
FEV1 is about 30 ml/year compared to the much higher
loss of lung function in smokers (FEV1 decline of 50
∗ Please address all correspondence to: J. T. Powell, Department of ml/year).11 Here we have investigated how smoking
Vascular Surgery, Imperial College at Charing Cross, St. Dunstans and lung function, measured as FEV1 and FVC, in-Road, London W6 8RP, U.K.
fluence operative and late mortality and risk of an-† The members of the Committee and Trial Participants are listed
in the Appendix. eurysm rupture for patients with small AAA. An
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earlier analysis of patients in the UK Small Aneurysm
Trial has shown that poor lung function was associated
with an increased length of hospital stay following
elective surgical repair and hence costs of the pro-
cedure.5,12 Perhaps surprisingly, the self-reported
smoking status of patients in the UK Small Aneurysm
Trial had no effect on long-term survival.4 In this
report, we have used plasma cotinine (the long-lived
stable metabolite of nicotine) as an objective marker
of smoking. This has allowed us to assess more ac-
curately the effects of smoking to highlight poor pro-
gnosis of current smokers with respect to mortality
and aneurysm rupture.
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Fig. 1. Survival stratified by self-reported smoking status at ran-
domisation. Kaplan–Meier estimates, log rank p=0.02.Methods
performed. Aneurysm rupture was ascertained eitherThe methods have been described elsewhere.3,4 Briefly,
from the death certificate or from imaging andpatients (aged 60–76 years) were entered into either
operative details. The cause of death in 92 patientsthe UK Small Aneurysm Trial or the Small Aneurysm
(29% of deaths) was determined after autopsy and aStudy from 93 hospitals across Britain. Fit patients
further 152 patients (49% of deaths) died in hospital.who consented to randomisation in the Trial had an
abdominal aortic aneurysm (AAA) 4.0–5.5 cm in dia-
meter. In total, 1090 patients were randomised in the Data analysis
4-year period from September 1991: 527 of these were
allocated to serial ultrasonographic surveillance and Statistical analysis for all-cause mortality and an-
563 to early elective surgery.4 Nearly all patients (93%) eurysm rupture was undertaken according to a pre-
adhered to the allocated treatment according to pro- defined plan, based on the total pool of 1090 patients.
tocol. Patients in the surveillance arm were followed Patients were censored at 30 June, 1998 (the end of
up at 6-monthly intervals until the aneurysm reached the trial), or if death had occurred earlier. For analysis
5 cm in diameter and 3-monthly thereafter. Surgical of aneurysm rupture patients were also censored at the
repair was recommended when the aneurysm dia- time of aneurysm repair. We compared Kaplan–Meier
meter exceeded 5.5 cm, the aneurysm became tender survival curves for time since randomisation or from
or had symptoms attributed to it, or the growth rate initial aortic diameter measurement to aneurysm rup-
exceeded 1 cm/year. By the end of the trial (30 June, ture with a log-rank test. We used Cox’s proportional
1998) 841 patients had undergone aneurysm repair, hazards regression to estimate hazard ratios for mor-
520 in the surgical arm and 321 in the surveillance tality (adjusted for age, sex, initial aneurysm diameter,
arm, the age–sex-adjusted 30-day mortality was 5.8% mean ankle/brachial pressure index, FEV1 use of as-and 7.1% respectively. Baseline blood samples were pirin, source of referral and treatment group). Sim-
analysed for haemoglobin, full blood count, elec- ilarly, we used Cox’s proportional hazards regression
trolytes and creatinine, cholesterol and cotinine. to estimate hazard ratios for rupture and to adjust
Plasma cotinine was analysed by radioimmunoassay these for age, sex and initial aneurysm diameter.
(EURO/DPC Ltd., Caernarfon, U.K.), coefficient of
variation 7%. The physiological measurements, in-
cluding aneurysm diameter and lung function with a Results
portable spirometer (Micromedical, Rochester, U.K.)
were performed by five specially trained trial co- Long-term survival
ordinators. These co-ordinators met every 6 months
to ensure uniformity and reproducibility of meas- At randomisation 404 (37%) patients reported as cur-
rent smokers, 620 (57%) as ex-smokers and 64 (6%)urements. All patients were flagged at the Office of
National Statistics to enable us to receive automatic claimed that they had never smoked. Kaplan–Meier
and univariate analyses suggested that currentnotification of emigration, death, place of death, under-
lying cause of death and whether an autopsy was smokers had a worse survival than ex-smokers (Fig.
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Table 1. The effect of self-reported smoking status and plasma cotinine concentration on mortality.
Factor Number of deaths/ Crude death rate Unadjusted hazard/ Adjusted hazard/ Adjusted
number of patients (per 100 person-years) ratio (95% CI) ratio (95% CI) p-value∗
Smoking status
Current 113/404 8.7 1.36 (1.08–1.71) 1.26 (0.98–1.61)
Ex-smoker 159/620 6.4 1.0 1.0 0.21
Never 17/64 6.5 1.0 (0.61–1.65) 1.09 (0.63–1.87)
p=0.03
Cotinine
concentration
(nmoles/l)
None 125/561 5.4 1.10 per 500 nmoles/l 1.08 per 500 nmoles/l
2–767 82/248 8.4 (1.04–1.16) (1.01–1.15) 0.02
768–11569 75/247 8.0 p=0.002
∗Adjusted for baseline factors, randomised treatment group, age, sex, initial aneurysm diameter, mean of left and right ABPI, FEV1 aspirin
life, source of referral, regional centre and type of hospital (teaching or district).
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Fig. 2. Survival stratified by plasma cotinine concentration. Five Fig. 3. Survival for patients stratified by FEV1 at randomisation.
hundred and sixty-one patients had cotinine recorded as zero. The patients have been divided into tertile groups. Kaplan–Meier
The remaining patients were divided around the median positive estimates, log rank p=0.001.
cotinine concentration to form two equally sized groups. Kaplan–
Meier estimates, log rank p=0.002.
2. The effect of FEV1 on survival is shown in Fig. 3
and in Table 1. After adjustment for baseline risk
1, Table 1). However, after adjustment for other pro- factors a very significant association between good
gnostic baseline variables the effect of current smoking lung function and survival remained, p=0.001 (Table
on survival was no longer significant (Table 1). 1). There was a similar relationship between high FVC
Plasma cotinine measurements were available for and improved survival (data not shown). There also
1056 (97%) patients. Cotinine was not detected in the was a very significant correlation between plasma
plasma of 561 (53%) of patients, indicating that they cotinine concentration and FEV1 recorded at baselinewere not current smokers. Plasma cotinine was meas- (Spearman’s p=0.0004).
urable in 495 (47%) of these 1056 patients, to indicate
current or very recent smoking: this inluded 103 of
the patients reporting as ex-smokers and 9 patients
who reportedly had never smoked. The apparently Rupture rates according to baseline variables
improved survival of patients with no detectable
plasma cotinine is shown in Fig. 2. The significance Among the 1090 randomised patients, there were 25
recorded abdominal aortic aneurysm ruptures. Onlyof this finding remained after adjustment for other
baseline prognostic variables, p=0.02 (Table 1). 15 of these ruptures occurred in patients where the
last recorded aneurysm diameter was less than 5.5 cm.Baseline lung function measurements (FEV1 and
FVC) were available for 1063 patients (98%) and strat- The remaining 10 ruptures occurred in patients where
the aneurysm had enlarged to >5.5 cm and were await-ified according to self-reported smoking status in Table
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Table 2. Self-reported smoking status, plasma cotinine concentration and lung function.
Smoking status Cotinine concentration FEV1 (l) FVC (l)
median (range) nmoles/l median (IQR) median (IQR)
Current (n=404) 810 (2–11569) [14] 2.0 (1.5–2.5) [14] 3.0 (2.4–3.5) [14]
Ex-smoker (n=620) 0 (0–4144) [16] 2.3 (1.7–2.7) [11] 3.2 (2.7–3.8) [11]
Never (n=64) 0 (0–1591) [4] 2.4 (1.7–2.7) [2] 3.1 (2.4–3.5) [2]
The number of missing values is shown in square brackets.
natural history of this condition and finding the best
management. The results of the UK Small Aneurysm
Trial have suggested that for most patients with small
aneurysms ultrasonographic surveillance is a safe, cost-
effective policy.4,5 The current findings indicate that, in
such patients, objective markers of smoking (plasma
cotinine) and poor lung function are strong predictors
of all-cause mortality after 6 years. Plasma cotinine
also was strongly associated with aneurysm rupture.
Smoking status appeared to have been inaccurately
reported by 10% of patients and has again proved
unreliable as an indicator of smoking habit. This un-
reliability of patient-reported habit probably explains
why self-reported smoking status was not associated
with all-cause mortality.4 Plasma (or urinary) cotinine
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is a test which is not routinely available. Under these
Fig. 4. Survival without rupture for patients stratified by plasma circumstances, lung function tests are likely to provide
cotinine concentration. Kaplan–Meier estimates, log rank p=0.004.
the most important prognostic indicator and guide to
patient management. Our findings confirm that, ining surgery (two), had become unfit for surgery (four),
patients with abdominal aortic aneurysm, continuedrefused surgery (two) or the planned repair had not
smoking shortens patient survival and increases the riskbeen completed because of other abdominal pathology.
of aneurysm rupture.The overall rupture rate in trial patients was 1% per
There are several previous examples to indicateyear. In eight patients the event was verified at surgical
that patients with vascular disease find it difficult torepair and 17 died without surgical repair (including
honestly report whether they continue to smoke. For15 deaths in hospital) and the event was recorded on
instance, self-reported smoking status has no effect onthe death certificate (including 10 autopsies). Of these
the outcome of vein bypass surgery but the use of aruptures 14 (56%) occurred in self-reported current
very long-lived smoking marker, plasma thiocyanate,smokers, but the increased risk of this group was only
showed that graft occlusion was twice as common inof borderline significance. In contrast, there were only
smokers as in those who no longer smoked.13,14 Nic-6 ruptures in patients with no trace of plasma cotinine
otine and its metabolites are more specific markers ofcompared with 19 ruptures in those with measurable smoking than thiocyanate. Nicotine has a short plasmaplasma cotinine, giving rupture rates of 0.5% per year half-life, but its principal metabolite, cotinine, has a
and 1.9% per year respectively, log rank p=0.004 (Fig. plasma half-life of 16 h. Therefore plasma cotinine
4). The increased risk for those positive for plasma assesses current or very recent smoking. In the UK
cotinine remained after adjustment for age, sex and Small Aneurysm Trial at least 103 patients appear to
initial aneurysm diameter, adjusted hazard ratio 3.33 have inaccurately reported themselves as ex-smokers
(95% CI 1.32–8.40), p=0.011. and nine patients appear to have inaccurately reported
themselves as never having smoked. Even this level
of inaccurate reporting (10%) has a significant effect
Discussion on the interpretation of results.
Continued smoking, as indicated by plasma cotinine,
Screening studies, in older men, have indicated that the was associated with poor survival prospects and in-
prevalence of small abdominal aortic aneurysms is 3–5%. creased risk of rupture for patients with small ab-
dominal aortic aneurysms. These findings areThis underscores the importance of understanding the
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